Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Cryopyrin-Associated Periodic Syndromes Clinical Trial

Official title:

An Open-label, Long-term Safety and Efficacy Study of ACZ885 (Anti-interleukin-1β Monoclonal Antibody) Administered for at Least 6 Months in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00685373
• Other study ID #: CACZ885D2306
• Status: Completed
• Phase: Phase 3
• First received: May 27, 2008
• Last updated: November 3, 2016
• Start date: May 2008
• Est. completion date: April 2010

Study information

• Verified date: September 2016
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationGermany: Paul-Ehrlich-InstitutSpain: Spanish Agency of MedicinesFrance: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)United Kingdom: Medicines and Healthcare Products Regulatory AgencyItaly: The Italian Medicines AgencyTurkey: Ministry of HealthIndia: Drugs Controller General of India
• Study type: Interventional

Clinical Trial Summary

This will provided long-term safety and efficacy data for ACZ885 (a fully human anti-interleukin-1β [anti-IL-1β] monoclonal antibody) given as an injection subcutaneously in patients who participated in the CACZ885A2102 (NCT00487708), CACZ885D2201 (NCT00685373) or CACZ885D2304(NCT00465985) studies or newly identified patients with the following cryopyrin-associated periodic syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome or Neonatal Onset Multisystem Inflammatory Disease.

The duration of this study was 6 months with a maximum duration of 2 years

Recruitment information / eligibility

• Status: Completed
• Enrollment: 166
• Est. completion date: April 2010
• Est. primary completion date: April 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 3 Years and older

Eligibility

Inclusion Criteria:

1. Male and female patients at least 3 years of age

2. Diagnosis of Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome or Neonatal Onset Multisystem Inflammatory Disease. Prior agreement between the Investigator and Novartis for study eligibility is required for patients who do not have a molecular diagnosis of NALP3 mutations available (either testing not performed, or testing performed but negative)upon study entry. For those patients who have not been molecularly tested for NALP3 mutations, molecular testing should be performed during the course of the study

3. For patients under anakinra therapy or any other investigational IL-1 blocking therapy, these treatments should be discontinued prior to the baseline visit.

4. Patients from the CACZ885A2102 study may enter this study. However, dosing at Visit 2 (Baseline Visit) can only occur if either 1) the patient is experiencing disease flare or 2) at least two months have elapsed from their last injection even in the absence of flare, whichever is earlier.

5. Patients who completed the CACZ885D2304 study may enter this study

6. Patients who completed the CACZ885D2201 study may enter this study

7. Patients who discontinued from the CACZ885A2102, CACZ885D2201 or CACZ885D2304 studies and for whom in the Investigator's judgment (with prior agreement from Novartis) continued treatment with ACZ885 in this study is considered appropriate.

Exclusion Criteria:

1. Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulation with the exception of trials with anakinra, other investigational IL-1 blocking therapies, and/or ACZ885.

2. History of being immunocompromised, including a positive HIV at screening (ELISA and Western blot) test result.

3. A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody test result is not allowed.

4. No live vaccinations within 3 months prior to the start of the trial, during the trial, and up to 3 months following the last dose.

5. History of recurrent and/or evidence of active bacterial, fungal, or viral infections.

6. Positive tuberculin skin test reaction (PPD 5 tuberculin units or as according to local standard practice) (>= 5 mm induration) at 48 to 72 hours after administration at the screening visit or within 2 months prior to the screening visit. Patients who have a positive PPD skin test with a documentation of BCG vaccination, who are at low environmental risk for tuberculosis (TB) infection or reactivation, and have a negative chest X-ray can be included.

Other protocol-defined inclusion/exclusion criteria may apply

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cellulitis
• Cryopyrin-Associated Periodic Syndromes
• Eosinophilia
• Familial Cold Autoinflammatory Syndrome
• Muckle Wells Syndrome
• Neonatal Onset Multisystem Inflammatory Disease
• Syndrome

Intervention

Drug:
• Canakinumab (ACZ885)
6 mL glass vial containing 150 mg lyophilized Canakinumab reconstituted with water for a subcutaneous injection every 8 weeks. Dosage based on body weight.

Locations

Country	Name	City	State
Belgium	Novartis Investigative Site	Laeken
France	Novartis Investigative Site	Le Kremlin Bicetre
France	Novartis Investigative Site	Lille Cedex
France	Novartis Investigative Site	Montpelier Cedex
France	Novartis Investigative site	Nantes
Germany	Novartis Investigative site	Berlin
Germany	Novartis Investigative Site	Hamburg
Germany	Novartis Investigative site	Heidelburg
Germany	Novartis Investigative Site	Herne
Germany	Novartis Investigative Site	Marburg
Germany	Novartis Investigative site	Tubingen
India	Novartis Investigative site	New Delhi
Italy	Novartis Investigative site	Genova
Italy	Novartis Investigative Site	Napoli
Italy	Novartis Investigative Site	Padova
Italy	Novartis Investigative Site	Rome
Italy	Novartis Investigative Site	Trieste
Spain	Novartis Investigative Site	Madrid
Spain	Novartis Investigative site	Oviedo
Spain	Novartis Investigative Site	Vigo
Turkey	Novartis Investigative site	Istanbul
United Kingdom	Novartis Investigative site	London
United States	Rush-Presbyterian St. Lukes Medical Center	Chicago	Illinois
United States	Cleveland Clinic	Cleveland	Ohio
United States	Allergy Center at Brookstone	Columbus	Georgia
United States	Little Rock Allergy and Asthma Clinic	Little Rock	Arkansas
United States	University of Wisconsin	Madison	Wisconsin
United States	UCSF School of Medicine	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
Novartis

Countries where clinical trial is conducted

United States,  Belgium,  France,  Germany,  India,  Italy,  Spain,  Turkey,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Number of Participants With Adverse Events (AEs), Death, Serious Adverse Events (SAEs), Discontinuation of Study Drug Due to an AE, Infections and Infestations and Injection Site Reactions	The number of participants with Adverse Events and Infections & Infestations are regardless of study drug relationship by primary system organ class preferred term equal and/or greater than 2% in any group. The number of participants with mild injection site reactions= mild reactions observed on at least one occasion but no moderate or severe reactions. The number of participants with moderate injection site reactions= moderate reactions observed on at least one occasion but no severe reactions.	2 years depending on when the participant enters the study	Yes
Secondary	The Percentage of Participants Without Disease Relapse as Determined by the Physician's Global Assessment of Autoinflammatory Disease Activity, Assessment of Skin Disease and Inflammation Markers.	Disease relapse following complete response is defined as inflammation markers: C-Reactive Protein (CRP) and/or Serum Amyloid A (SAA) result > 30 mg/L AND Physician's Global Assessment of Autoinflammatory Disease Activity > minimal or Physician's Global Assessment >= minimal AND Skin Disease Assessment > minimal.; Physician's Global Assessment of Autoinflammatory Disease Activity and Skin Disease Assessment (urticarial skin rash) are completed by the investigator using a 5 point rating scale: absent, minimal, mild, moderate and severe.	Every 8 weeks during the course of the trial for at least 6 months with a maximum duration of 2 years	No
Secondary	Immunogenicity of Canakinumab (ACZ885)	The number of participants who tested positive for anti-ACZ885 antibodies using the Biacore Assay at the end of the study.	Every 8 weeks during the course of the trial for at least 6 months with a maximum duration of 2 years	Yes
Secondary	Pharmacokinetics	Mean Clearance from serum in Liter per Day (CLD) in adult participants >=18, pediatric participants <18 with body weight >40 kg and pediatric participants <18 with body weight <=40 kg.	Every 8 weeks during the course of the trial for at least 6 months with a maximum duration of 2 years	No